Skip to Content
Hematology ReportsHematology Reports
  • Brief Report
  • Open Access

2 December 2020

4 Pages

Comparison of Post-Remission Strategies in Acute Myeloid Leukemia: Autologous Hematopoietic Stem Cell Transplantation versus Consolidation Chemotherapy

,
,
,
,
and
Department of Hematology, Gazi University School of Medicine, Beşevler, Ankara 06680, Turkey
*
Author to whom correspondence should be addressed.

Abstract

Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) has become a therapeutic option for first-line consolidation in Acute Myeloid Leukemia (AML) patients with favorable and intermediate risk features. A total of 101 AML patients in first complete remission, who were not eligible for allogeneic HSCT, were randomized to receive intensive cytarabine-based chemotherapy or to undergo auto-HSCT. The probability of LFS was significantly better in auto-HSCT recipients compared to chemotherapy arm (43% vs. 4.8%, p = 0.008). At the end of 915 (30–4470) days of followup, the probability of overall survival was better in auto-HSCT group compared to chemotherapy, without statistical significance (79.2% vs. 38.8%, p = 0.054). Multivariate analysis revealed a significant predictive impact of cytogenetic risk status on OS (p = 0.002, HR: 2.824, 95% CI: 1.445–5.521). Auto-HSCT is considered as an effective consolidation approach in favorable and intermadiate risk AML patients.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.